ArticleSurgery2026
Does neoadjuvant systemic therapy in clinical T1-2 N0 human epidermal growth factor receptor 2-positive breast cancer increase the extent of axillary surgery?
Article in Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundFor patients with human epidermal growth factor receptor 2-positive breast cancer, an upfront surgery or neoadjuvant systemic therapy approach can influence the need for axillary lymph node dissection depending on pathologic nodal status. This study aimed to evaluate the impact of an upfront surgery versus neoadjuvant systemic therapy approach in women with cT1-2 human epidermal growth factor receptor 2-positive breast cancer on pathologic nodal status and odds of axillary lymph node dissection.
methodsThis retrospective study used the National Cancer Database and included female patients aged ≥18 years, diagnosed between 2016 and 2021, with cT1-2 N0 M0 human epidermal growth factor receptor 2-positive breast cancer. Demographic, clinicopathologic, and treatment data were collected. Analyses included analysis of variance, Kruskal-Wallis, χ
resultsA total of 62,927 women met inclusion criteria: 66.6% (n = 39,024) underwent upfront surgery, and 33.4% (n = 19,562) received neoadjuvant systemic therapy. The neoadjuvant systemic therapy cohort was younger (mean age: 53.8 vs 59.9 years, P < .001), had fewer comorbidities (86.9% vs 82.7% with a Charlson-Deyo score of 0, P < .001), and more frequently had cT2 tumors (71.7% vs 21.7%, P < .001). On multivariable analysis, patients with upfront surgery were more likely to be pN+ (1-3 nodes: 14.7% vs 6.8%, odds ratio: 3.19, 95% confidence interval: 2.96-3.45 and ≥4 nodes: 2.0% vs 0.7%, odds ratio: 5.48, 95% confidence interval: 4.43-6.80); however, there was no difference in the odds of axillary lymph node dissection (odds ratio: 0.96, 95% confidence interval: 0.86-1.08).
conclusionPatients who underwent upfront surgery had a greater likelihood of being pN+; however, there was no difference in the likelihood of axillary lymph node dissection. Therefore, neoadjuvant systemic therapy use should be based on current systemic therapy guidelines and patient-centered shared multidisciplinary decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.